Oral Mucositis also called as stomatitis is an acute inflammation of the mucous membranes of mouth/oral cavity following the systemic cancer therapy and/or radiation therapy.

The most common cause of Oral Mucositis is cancer treatments. The frequent treatments of chemotherapy, radiation of the head, chest, or neck, bone marrow and stem cell transplants can cause mucositis.

Symptoms include dry mouth, shiny, swollen, or red gums, mouth pain, painful mouth sores, infection, blood in the mouth, pain or a mild burning sensation while eating, difficulty in swallowing or talking.

Doctors can generally make a diagnosis based on the timing of symptoms relative to therapy and the clinical appearance of mouth. There is no laboratory or radiographic testing that is needed to make the diagnosis. Because viral or fungal (yeast) infections can occur in mouth, especially if white blood cell count is low, a culture, or a scraping may be done to rule out an infection.

The most common treatments for Oral Mucositis are medication and mouthwashes and oral care.

Report Highlights

Global Insight Service’s, Oral Mucositis – Drug Pipeline Landscape, 2022 report provides an overview of the Oral Mucositis pipeline drugs. This report covers detailed insights on Oral Mucositis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Oral Mucositis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents

List of Tables
List of Figures

1. Introduction
1.1 Oral Mucositis – Pipeline Drugs, 2022-Coverage

2. Disease Overview – Oral Mucositis
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management

3. Oral Mucositis – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022

4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration

5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1. SGX942
5.2 Clinical Stage Drugs – Phase II
5.2.1 Avasopasem Manganese
5.2.2 EC-18
5.2.3 MBM-01
5.2.4 MIT-001
5.2.5 Validive
5.3 Early Stage Drugs – Preclinical
5.3.1 CNT101
5.3.2 CVXL-0095
5.3.3 NG11-1
5.3.4 NG11-2
5.3.5 Nu-8
5.3.6 Tat-PYC-Smad7
5.3.7 XF-73

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved
9.1 Allander Biotechnologies LLC
9.2 Clevexel Pharma SA
9.3 Connext Co Ltd
9.4 Destiny Pharma
9.5 Enzychem Lifesciences Corporation
9.6 Galera Therapeutics, Inc
9.7 Lakewood-Amedex, Inc
9.8 Matrix Biomed, Inc.
9.9 MitoImmune Therapeutics
9.10 Monopar Therapeutics
9.11 VasoDynamics
9.12 Soligenix

10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs

11. Appendix

List of Tables

Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – SGX942/Soligenix
Table 2.2 Clinical Trial Details – Avasopasem Manganese/Galera Therapeutics, Inc.
Table 2.3 Clinical Trial Details – EC-18/Enzychem Lifesciences Corporation
Table 2.4 Clinical Trial Details – MBM-01/Matrix Biomed, Inc.
Table 2.5 Clinical Trial Details – MIT-001/MitoImmune Therapeutics
Table 2.6 Clinical Trial Details – Validive/Monopar Therapeutics
Table 2.7 Clinical Trial Details – CNT101/Connext Co Ltd
Table 2.8 Clinical Trial Details – CVXL-0095/Clevexel Pharma SA
Table 2.9 Clinical Trial Details – NG11-1/VasoDynamics
Table 2.10 Clinical Trial Details – NG11-2/VasoDynamics
Table 2.11 Clinical Trial Details – Nu-8/Lakewood-Amedex, Inc.
Table 2.12 Clinical Trial Details – Tat-PYC-Smad7/Allander Biotechnologies LLC
Table 2.13 Clinical Trial Details – XF-73/Destiny Pharma
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs

List of Figures

Figure 1. 1 Number of Products under Development for Oral Mucositis , 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Oral Mucositis , 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Oral Mucositis , 2022
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Oral Mucositis , 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Oral Mucositis , 2022

Report Segmentation
  • Assessment by Stage of Development
  • Assessment by Companies
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Molecule Type
  • Assessment by Route of Administration

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Premature ejaculation is a type of sexual dysfunction…
Irritable bowel syndrome (IBS) is a group of…
The H1N1 flu (swine flu) is primarily caused…